ArticleBMC anesthesiology2025
Anesthesia information system-assisted detection and effective management of sugammadex-induced anaphylaxis: a case report.
Article in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSugammadex, a neuromuscular blockade reversal agent, has a reported incidence of severe anaphylaxis of approximately 0.005% in Japan, typically occurring within 5 min of administration. However, detailed case reports describing the full clinical course and associated changes in monitoring parameters—such as vital signs, capnographic waveforms, and airway pressure—remain limited. CASE PRESENTATION: We report the case of an 80-year-old man who underwent laparoscopic partial hepatectomy under combined general and epidural anesthesia. Postoperatively, 200 mg of sugammadex was administered to reverse neuromuscular blockade. Within 2 min, the ventilator’s high airway pressure alarm was triggered, and capnography showed an obstructive pattern as ventilation became difficult. Suspecting a severe asthma attack, we initiated treatment with 3% sevoflurane for bronchodilation and administered 0.3 mg of intramuscular adrenaline. A full-body examination revealed a red rash on the upper abdomen and redness with edema of the eyelids, confirming an anaphylactic reaction. Sugammadex-induced anaphylaxis was diagnosed. The systolic blood pressure had transiently dropped to 71 mmHg but improved with a single 0.15 mg dose of phenylephrine. Extubation was delayed due to marked upper airway edema and an incompletely normalized capnographic pattern of obstruction; the patient was maintained on mechanical ventilation under deep sedation until safe extubation on postoperative day 1.
conclusionsSugammadex-induced anaphylaxis can occur rapidly following administration. This case highlights the value of continuous electronic monitoring, which enabled documentation of detailed real-time changes in vital signs, capnography, and airway pressure from the onset of bronchospasm to recovery. Given persistent bronchospasm despite adequate oxygenation, mechanical ventilation was continued with the patient intubated and sedated. Such comprehensive monitoring data provide important insights for the early recognition and management of intraoperative anaphylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.